Human β defensins-1, an antimicrobial peptide, kills Candida glabrata by generating oxidative stress and arresting the cell cycle in G0/G1 phase - 10/09/22
Abstract |
Candida glabrata is the most frequently isolated non-albicans Candida species in clinical samples and is known to develop resistance to commonly used antifungal drugs. Human β defensins (hBDs) are antimicrobial peptides of immune systems and are active against a broad range of pathogens including Candida species. Herein, the antifungal effect of hBD-1 and its mechanism of action in C. glabrata was studied. The antifungal susceptibility of hBD-1 against C. glabrata was calculated by broth microdilution assay. To study the mechanism of antifungal action, the impact of hBD-1 on cell cycle, expression of oxidative stress enzymes, and membrane disintegration were assessed. The susceptibility results confirmed that hBD-1 possessed the minimum inhibitory concentration of 3.12 µg/mL and prevented the growth and caused yeast cell death to various extents. The peptide at subinhibitory and inhibitory concentrations blocked the cell cycle in C. glabrata in G0/G1 phase and disturbed the activity of primary and secondary antioxidant enzymes. Furthermore, at higher concentrations disruption of membrane integrity was observed. Altogether, hBD-1 showed candidicidal activity against C. glabrata and was able to induce oxidative stress and arrested cell cycle in C. auris and therefore has a potential to be developed as an antifungal drug against C. glabrata.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Human β defensins-1 significantly inhibits growth and survival of C. glabrata. |
• | Human β defensins-1 modulates activity of crucial antioxidant enzymes. |
• | Human β defensins-1 displayed the potency to arrest cell cycle in G0/G1 phase. |
• | Human β defensins-1 has the tendency to disrupt membrane integrity and alters cellular morphology of C. glabrata. |
Abbreviations : CAT, SOD, GPx, GLR, GST
Keywords : Candida glabrata, Human β-defensins-1, Antimicrobial peptides, Cell cycle arrest, Antioxidant enzymes
Plan
Vol 154
Article 113569- octobre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?